Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Inclusion Criteria: 1. Age≥18 years, male or female; 2. Karnofsky≥60%； 3. B cell lymphoma patients who are not available for the following treatment: autologous stem cell transplantation, allogeneic stem cell transplantation, or patients with short expected survival (less than 2 years). 4. Patients with CR2 or CR3 and no stem cell transplantation available due to age, disease condition, lack of donors or any other reasons. 5. Patients have had more than 2 combined chemotherapy regimens; 6. Creatinin \<2.5mg/dL；ALT/AST level \<3 times of the maximum of normal range; bilirubin\<3mg/dL； 7. Proper venous condition for leukapheresis, no contraindication for leukapheresis; 8. Patient that could understand and is willing to sign the written consent; 9. Fertile female patient should be willing to take contraceptive measures. 10. Patient that is willing to follow up till at least 2 months after T cell re-transfusion. Exclusion Criteria: 1. Patients who need ≥15mg prednisone daily due to any cause; 2. Patients with autoimmune disease and need immunosuppressor treatment; 3. Serum creatinin\>2.5 mg/dL；serum AST \>5 times of normal maximum; bilirubin \>3 mg/Dl; 4. FEV1\<2 L，diffusion capacity for carbon monoxide of lung (DLCO) \<40%； 5. Cardiovascular abnormalities that fulfill any of the following: NYHA level III or IV congestive heart failure, severe clinical hypotention; uncontrollable carotid heart disease; or ejection fraction\<35%； 6. Patients with HIV infection, active Hepatitis B or Hepatitis C infection; 7. Patients that have previously received gene therapy of any kind; 8. Obvious clinical encephalopathy or novel neuron function damage; 9. Patients with active infection; 10. Patients had biological treatment, immunotherapy or radiation therapy within 1 month prior to enrollment or are currently under these treatment; 11. Patients who had allergic history to agents of the similar structure as CAR-T;